What insurance policy changes affect HCPCS J9190?

There are 15 tracked policy changes affecting HCPCS J9190, including updates from Kansas Medicaid (KanCare), Independence Blue Cross, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS J9190?

Payers that have issued tracked updates for HCPCS J9190 include: Kansas Medicaid (KanCare), Independence Blue Cross, Aetna, Highmark.

How do I get notified when HCPCS J9190 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS J9190. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for HCPCS J9190?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

J9190 — Injection, fluorouracil, 500 mg: Insurance Policy Changes

J9190 Insurance Policy Changes

HCPCS J9190 is officially defined as "Injection, fluorouracil, 500 mg." HCPCS J9190 is referenced in 15 tracked payer policy changes from Kansas Medicaid (KanCare), Independence Blue Cross, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J9190 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

High impact

Irinotecan Liposome Injection (Onivyde) (CPB 0902, reviewed 2026-02-24)

Aetna·Effective Feb 24, 2026

Aetna has updated its coverage policy for Irinotecan Liposome Injection (Onivyde) effective immediately, establishing specific medical necessity criteria for ampullary adenocarcinoma and pancreatic adenocarcinoma treatments. The policy defines approved indications including first-line NALIRIFOX regimens, subsequent therapy scenarios, and dosing requirements, while designating all other uses as experimental/investigational. Billing teams must verify patient diagnoses, treatment lines, prior therapy history, and performance status documentation before processing claims for HCPCS code J9205.

J9190 Insurance Policy Changes

KMAP BULLETIN: HCPCS Codes Update – October 2026

MA05.060h, External Infusion Pumps

Glaucoma Surgery (CPB 0484, reviewed 2026-07-14)

Ramucirumab (Cyramza) (CPB 0883, reviewed 2026-06-03)

Prior Authorization Changes to Oncology-related Codes

Irinotecan Liposome Injection (Onivyde) (CPB 0902, reviewed 2026-02-24)

Panitumumab (Vectibix) (CPB 0748, reviewed 2025-12-23)

Levoleucovorin (Khapzory) (CPB 0889, reviewed 2025-12-04)

Glaucoma Surgery (CPB 0484, reviewed 2026-10-14)

11.08.25p, Scar Revision

MA08.007ay, Medicare Part B vs. Part D Crossover Drugs

MA11.078e, Scar Revision

11.08.25o, Scar Revision

Ziv-Aflibercept (Zaltrap) (CPB 0842, reviewed 2025-12-09)

11.08.25n, Scar Revision